Every 10-Q that Incannex Healthcare Limited (IXHL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IXHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IXHL filings page.
Incannex Healthcare Inc. reported no revenue and a net loss of $3.9M for the quarter and $16.8M for the nine months ended March 31, 2026. Operating expenses totaled $4.0M for the quarter, with research and development at $0.3M and general and administrative at $3.7M, the latter driven largely by higher stock-based compensation.
Cash and cash equivalents rose to $74.5M as of March 31, 2026, up from $15.0M at June 30, 2025, mainly due to equity financings including a $10.0M March 2026 registered direct offering. Stockholders’ equity increased to $75.2M. The company effected a 1-for-30 reverse stock split in February 2026.
Incannex continues to incur operating losses but believes its cash will fund operations for at least twelve months. It also has a $20M share repurchase program and has repurchased 2.1M shares to date for about $9.1M. Management discloses an ongoing material weakness in internal control over financial reporting and is implementing remediation measures.
Incannex Healthcare reported no revenue for the quarter ended December 31, 2025, reflecting its status as a clinical-stage biopharmaceutical company. Net loss was $6.5 million for the quarter and $12.9 million for the six months, driven mainly by research and development and higher general and administrative expenses, including increased stock-based compensation.
Cash and cash equivalents rose sharply to $68.9 million from $15.0 million at June 30, 2025, primarily from equity issuances, partially offset by operating cash burn of $13.8 million and $1.5 million of share repurchases under a $20 million buyback program. Management believes existing cash will fund operations for at least 12 months, but the company continues to post sizable losses as it advances key programs, including its IHL-42X Phase 2/3 sleep apnea trial and other Phase 2 assets.
The company reiterates that it remains in a development phase with no product revenue and discloses an ongoing material weakness in internal control over financial reporting related to complex accounting, which it is attempting to remediate through added policies, training and control resources.
Incannex Healthcare Inc. (IXHL) reported its September 30, 2025 quarter with higher liquidity and a wider loss. The company recorded a net loss of $6.4 million versus $5.4 million a year ago as general and administrative expenses rose to $5.7 million. Research and development expense decreased to $1.1 million, reflecting trial timing and program resourcing.
Liquidity strengthened materially during the quarter. Cash and cash equivalents increased to $73.3 million from $15.0 million, driven by share issuances that provided $69.5 million in gross proceeds and $67.2 million net cash from financing. Stockholders’ equity rose to $77.0 million from $13.4 million. The company stated its cash should fund planned operations for at least twelve months from these financial statements. Shares issued and outstanding were 347,705,507 at quarter-end; as of November 14, 2025, shares outstanding were 346,225,507 following a buyback of 1,480,000 shares at $0.41 per share.
Operations and programs continued. The Phase 2/3 RePOSA trial for IHL-42X remained the primary R&D spend driver. Revenue from customers was zero for the quarter. The company maintained its prior disclosure of a material weakness in internal control over financial reporting and outlined ongoing remediation steps.